Maja J.A. de Jonge

4.7k citations

108 papers · 3.1k · h-index 33

Impact in

Oncology top 2%
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
Molecular Biology top 5%
- Cancer therapeutics and mechanisms
- RNA Research and Splicing

Papers in

Molecular Biology 45
- Cancer therapeutics and mechanisms 30
Oncology 44
- Lung Cancer Research Studies 10
- Neutropenia and Cancer Infections 9
- PARP inhibition in cancer therapy 7
- Cancer Treatment and Pharmacology 6

Co-authors: Jaap Verweij (50 shared papers)Alex Sparreboom (26 shared papers)Ferry A.L.M. Eskens (16 shared papers)Ron H.J. Mathijssen (14 shared papers)Walter J. Loos (17 shared papers)André Planting (13 shared papers)Floris A. de Jong (4 shared papers)Kees Nooter (7 shared papers)
Journals: Annals of Oncology (17 papers)European Journal of Cancer (15 papers)Journal of Clinical Oncology (14 papers)Clinical Cancer Research (10 papers)Investigational New Drugs (8 papers)
Partner nations: Netherlands United States Belgium

In The Last Decade

Maja J.A. de Jonge

108 papers receiving 3.1k citations

Peers

Countries citing papers authored by Maja J.A. de Jonge

Since Specialization

Citations

This map shows the geographic impact of Maja J.A. de Jonge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maja J.A. de Jonge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maja J.A. de Jonge more than expected).

Fields of papers citing papers by Maja J.A. de Jonge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maja J.A. de Jonge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maja J.A. de Jonge. The network helps show where Maja J.A. de Jonge may publish in the future.

Co-authors

The 25 scholars most cited alongside Maja J.A. de Jonge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maja J.A. de Jonge Line = papers co-authored together Maja J.A. de Jonge links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 108 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Ferry A.L.M. Eskens, Francisco Javier Ramos, Herman Burger, James P. O’Brien, Adelaida Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, José Baselga, Josep Tabernero	2013	195
2	Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma British Journal of Cancer ·J M W van Haarst, (unknown), C. Manegold, J.H. Schouwink, J.A. Burgers, Hein G. de Bruin, W. J. Mooi, R.J. van Klaveren, Maja J.A. de Jonge, Jan P. van Meerbeeck	2002	115
3	Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure Journal of Clinical Oncology ·Felix E. de Jongh, Jaap Verweij, Walter J. Loos, Ronald de Wit, Maja J.A. de Jonge, André Planting, Kees Nooter, G. Stoter, Alex Sparreboom	2001	96
4	Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Ferry A.L.M. Eskens, Ahmad Awada, David L. Cutler, Maja J.A. de Jonge, Gré P.M. Luyten, M.N. Faber, Paul Statkevich, Alex Sparreboom, Jaap Verweij, Axel‐R. Hanauske, Martine Piccart	2001	94
5	Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia Journal of Clinical Oncology ·Jessica M. van der Bol, Ron H.J. Mathijssen, Walter J. Loos, Lena E. Friberg, Ron H. N. van Schaik, Maja J.A. de Jonge, André Planting, Jaap Verweij, Alex Sparreboom, Floris A. de Jong	2007	92
6	Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors Journal of Clinical Oncology ·Neeltje Steeghs, Ferry A.L.M. Eskens, Hans Gelderblom, Jaap Verweij, J.W.R. Nortier, Jan Ouwerkerk, Conny van Noort, Mariangela Mariani, R. Spinelli, Patrizia Carpinelli, B. Laffranchi, Maja J.A. de Jonge	2009	90
7	Role of pharmacogenetics in irinotecan therapy Cancer Letters ·Floris A. de Jong, Maja J.A. de Jonge, Jaap Verweij, Ron H.J. Mathijssen	2005	90
8	Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours British Journal of Cancer ·Nienke A. G. Lankheet, Jacqueline S. L. Kloth, Christa G.M. Gadellaa-van Hooijdonk, Geert A. Cirkel, Ron H.J. Mathijssen, Martijn P. Lolkema, Jan H.M. Schellens, Emile E. Voest, Stefan Sleijfer, Maja J.A. de Jonge, John B.A.G. Haanen, Jos H. Beijnen, Alwin D. R. Huitema, Neeltje Steeghs	2014	89
9	Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors Clinical Cancer Research ·Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij	2011	88
10	Aurora kinase inhibitors Critical Reviews in Oncology/Hematology ·Jos Kitzen, Maja J.A. de Jonge, Jaap Verweij	2009	83
11	Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours European Journal of Cancer ·Maja J.A. de Jonge, Herlinde Dumez, Jaap Verweij, Shai Yarkoni, David S. Snyder, Denis Lacombe, Sandrine Marréaud, Tadashi Yamaguchi, Cornelis J.A. Punt, A. van Oosterom	2006	80
12	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours British Journal of Cancer ·Mark T. J. van Bussel, Ahmad Awada, Maja J.A. de Jonge, Morten Mau‐Sørensen, Dorte Nielsen, Patrick Schöffski, Henk M.W. Verheul, Barbara Sarholz, Karin Berghoff, Samer El Bawab, Mirjam Kuipers, Lars Damstrup, Iván Díaz-Padilla, Jan H.M. Schellens	2020	79
13	Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours European Journal of Cancer ·Jos Kitzen, Maja J.A. de Jonge, C. B. H. W. Lamers, Ferry A.L.M. Eskens, D. van der Biessen, Leni van Doorn, Judith ter Steeg, M. Brandely, Ch. Puozzo, Jaap Verweij	2009	78
14	Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for **UGT1A128*** Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled Study The Oncologist ·Floris A. de Jong, Diederik F.S. Kehrer, Ron H.J. Mathijssen, Geert‐Jan Creemers, Peter de Bruijn, Ron H. N. van Schaik, André Planting, Ate van der Gaast, Ferry A.L.M. Eskens, J Janssen, Jan B. Ruit, Jaap Verweij, Alex Sparreboom, Maja J.A. de Jonge	2006	76
15	Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation European Journal of Cancer ·Maja J.A. de Jonge, Marije Slingerland, Walter J. Loos, Erik A.C. Wiemer, Herman Burger, Ron H.J. Mathijssen, Judith R. Kroep, Margret A.G. den Hollander, D. van der Biessen, Mei-Ho Lam, Jaap Verweij, Hans Gelderblom	2010	73
16	Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces Journal of Chromatography B Biomedical Sciences and Applications ·Alex Sparreboom, Peter de Bruijn, Maja J.A. de Jonge, Walter J. Loos, Gerrit Stoter, Jaap Verweij, Kees Nooter	1998	72
17	Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors Clinical Cancer Research ·Otto Soepenberg, Herlinde Dumez, Jaap Verweij, Floris A. de Jong, Maja J.A. de Jonge, José Thomas, Ferry A.L.M. Eskens, Ron H. N. van Schaik, Johan Selleslach, Judith ter Steeg, (unknown), Sylvie Assadourian, Ger‐Jan Sanderink, Alex Sparreboom, Allan T. van Oosterom	2005	70
18	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation Clinical Cancer Research ·Martijn P. Lolkema, Hilde Bohets, Hendrik‐Tobias Arkenau, Ann Lampo, Erio Barale-Thomas, Maja J.A. de Jonge, Leni van Doorn, Peter Hellemans, Johann S. de Bono, Ferry A.L.M. Eskens	2015	69
19	Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Otto Soepenberg, Maja J.A. de Jonge, Alex Sparreboom, Peter de Bruin, Ferry A.L.M. Eskens, Gerda de Heus, J. Wanders, Peter Cheverton, Murray P. Ducharme, Jaap Verweij	2005	56
20	Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects Journal of Clinical Oncology ·Maja J.A. de Jonge, Walter J. Loos, Hans Gelderblom, André Planting, Maria E.L. van der Burg, Alex Sparreboom, Eric Brouwer, V van Beurden, Marijke Mantel, E. Doyle, S Hearn, Graham Ross, Jaap Verweij	2000	56

About Maja J.A. de Jonge

Maja J.A. de Jonge is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Immunology and Cell Biology, having authored 108 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (30 papers), Lung Cancer Research Studies (10 papers), Neutropenia and Cancer Infections (9 papers), PARP inhibition in cancer therapy (7 papers), Microtubule and mitosis dynamics (6 papers), Immune cells in cancer (6 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Oncology (1.1k citations), Molecular Biology (1.5k citations), Pulmonary and Respiratory Medicine (484 citations), Toxicology (50 citations) and Genetics (148 citations). Maja J.A. de Jonge has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Jaap Verweij, Alex Sparreboom, Ferry A.L.M. Eskens, Ron H.J. Mathijssen, Walter J. Loos, André Planting, Floris A. de Jong, Kees Nooter, Jos Kitzen and Herman Burger. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, Clinical Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Maja J.A. de Jonge

Impact in

Papers in i

In The Last Decade

Maja J.A. de Jonge

Peers

Countries citing papers authored by Maja J.A. de Jonge

Fields of papers citing papers by Maja J.A. de Jonge

All Works

About Maja J.A. de Jonge

Explore authors with similar magnitude of impact

Papers in